Intelligent Investing News
Intelligent Investing News
|
Merger Arbitrage Mondays: September 06, 2010
|
|
|
UPDATE - Market Chatter -- Corporate finance press digest
|
|
|
Sanofi ready to raise bid if Genzyme talks -report
|
|
|
Genzyme, Sanofi May Eventually Come to Terms: Focus on Biotech Deals
|
|
|
[$$] Follow-Up
|
[at Barrons.com] - Sanofi Aventis offers $69 a share in cash for Genzyme. Could the money be better deployed in buying back Sanofi stock? The CEO says no.
|
|
[$$] Review
|
[at Barrons.com] - Grooming index rises to a record despite economy.
|
|
Top Ten: MarketWatch's Top 10 stories: Aug. 30-Sept. 3
|
[at MarketWatch] - As the week winds down, with stocks having lodged their best pre-Labor Day week in decades, the Dow industrials are back in the black for 2010. Take a look at MarketWatch's top 10 markets, news, feature and personal-finance stories.
|
|
Stock Market Isn't Impressed With M&A Boom
|
|
|
History Predicts Genzyme Will Sell For $80 Per Share
|
[at Minyanville] - A historical analysis of unsolicited bids shows that there's a high likelihood Genzyme will be acquired by someone.
|
|
Genzyme's Termeer Could Sell Company
|
|
|
[video] More Hostile Biotech, Pharma Deals
|
|
|
RPT-SCENARIOS-Possible outcomes of Sanofi's bid for Genzyme
|
|
|
Future of Genzyme / Isis Pharma's Cholesterol Drug Still Up in the Air
|
|
|
Pfizer Takes an Orphan Into the Fold
|
|
|
[video] Pfizer and Merck to Make Acquisitions
|
|
|
A new M&A boom? Not so fast.
|
[at Fortune] - Last month was the busiest August on record for global M&A activity, but this small sign of encouragement doesn't yet translate to a comeback.
|
|
UPDATE - Side effects of Isis' mipomersen meet expectations
|
|
|
Sanofi Ups The Pressure On Genzyme
|
|
|
Don't Let It Happen, Celgene
|
|
|
Human Capital: People on the move, Sept. 1
|
|
Intelligent Investing News
Intelligent Investing News
|
UPDATE: Sanofi Prepared To Raise Genzyme Bid If Genzyme Talks - Source
|
(Source: Dow Jones Newswires)
|
|
Sanofi Prepared To Raise Genzyme Bid If Genzyme Talks - Source
|
By Jessica Hodgson and Marietta Cauchi Of DOW JONES NEWSWIRES... (Source: Dow Jones Newswires)
|
|
The Unusual Suspects for the Week Ahead (BKS, BRCD, CSKI, CIEN, FNFG, NAL, GENZ, SNY, LULU, ID, NFLX, NE, PBR, RTN, SKS, TTWO, THQI, CALL)
|
(Source: 24/7 Wall St)
|
|
Follow-Up
|
(Source: Barrons.com)
|
|
Review
|
(Source: Barrons.com)
|
|
MarketWatch's Top 10 stories: Aug. 30-Sept. 3
|
(Source: MarketWatch.com)
|
|
Stock Market Isn't Impressed With M&A Boom
|
(Source: WSJ.com)
|
|
Rare diseases are the new black.
|
(Source: The Motley Fool)
|
|
UPDATE: Total CEO Won't Comment On Sanofi Offer Price For Genzyme
|
French oil major Total SA (TOT, FP.FR) Chairman and Chief Executive Christophe de Margerie on Wednesday declined to comment on the price offered by Sanofi Aventis (SNY) for U.S. biotech Genzyme Corp (GENZ).... (Source: Dow Jones Newswires)
|
|
Total CEO Won't Comment On Sanofi Price For Genzyme
|
French oil major Total SA (TOT) Chairman and Chief Executive Christophe de Margerie on Wednesday declined to comment on the price offered by Sanofi Aventis (SNY) for U.S. biotech Genzyme Corp (GENZ).... (Source: Dow Jones Newswires)
|
|
Keep ahead of Wall Street with this secret tool.
|
(Source: The Motley Fool)
|
|
A.M. Vitals: Genzyme Says Sanofi Needs to Cough Up More Cash
|
(Source: WSJ.com)
|
|
Media Digest 9/1/2010 Reuters, WSJ, NYTimes, FT, Bloomberg
|
(Source: 24/7 Wall St)
|
|
Data from Mipomersen Phase 3 Trial in heFH -2-
|
This press release contains forward-looking statements regarding Genzyme's business plans and strategies regarding mipomersen including, without limitation, statements about its potential uses, its safety... (Source: Press Release)
|
|
Data from Mipomersen Phase 3 Trial in heFH Patients Presented at ESC
|
Study Meets Primary Endpoint with 28 Percent LDL-C Reduction Genzyme Corp. (NASDAQ: GENZ) and Isis Pharmaceuticals Inc. (NASDAQ: ISIS) announced that data from the phase 3 study of mipomersen in patients... (Source: Press Release)
|
